The U.S. Food and Drug Administration (FDA) on Monday warned against using a combination of anti-malaria drug hydroxychloroquine and Gilead's experimental remdesivir on Covid-19 patients, as it could substantially reduce the effectiveness of the drug. The announcement came hours after the FDA revoked the emergency use of hydroxychloroquine as a potential Covid-19 treatment.